Alkermes vs Kiniksa Pharmaceuticals International

Alkermes (ALKS), health care, and Kiniksa Pharmaceuticals International (KNSA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alkermes is worth $7.6B on the stock market and Kiniksa Pharmaceuticals International $7.5B: Alkermes is valued at 2% more. Alkermes's operating margin in its latest fiscal year was 17.2% and Kiniksa Pharmaceuticals International's 11.4%. Over the past year Alkermes's share price has moved +59.0% and Kiniksa Pharmaceuticals International's +128%.

Key facts

Alkermes market value
$7.6B
Kiniksa Pharmaceuticals International market value
$7.5B
Kiniksa Pharmaceuticals International P/E
72.1
Alkermes revenue
$1.5BFY to 2025-12-31
Kiniksa Pharmaceuticals International revenue
$677.6MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Alkermes vs Kiniksa Pharmaceuticals International: every measure side by side
Measure Alkermes Kiniksa Pharmaceuticals International
SectorHealth CareHealth Care
Country Ireland United Kingdom
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.6Bhigher$7.5Blower
Revenue$1.5Bhigher$677.6Mlower
Earnings$241.7Mhigher$59Mlower
Employees2,050higher366lower
Total assets$2.5Bhigher$763.6Mlower
Valuation
P/E—72.1
P/S5.2lower11.0higher
P/B——
Dividend yield——
Profitability
Operating margin17.2%higher11.4%lower
Balance sheet
Net assets$1.8Bhigher$567.6Mlower
Total liabilities$667.7Mhigher$196Mlower
Total debt——
Cash on hand$388.6Mhigher$165.6Mlower
Price change
Today-2.32%lower+0.93%higher
1 year+59.0%lower+128%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Kiniksa Pharmaceuticals International only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Alkermes / Kiniksa Pharmaceuticals International). Who owns ALKS · Who owns KNSA

Further comparisons

Learn

Questions and answers

Which is bigger, Alkermes or Kiniksa Pharmaceuticals International?

By market value, Alkermes is the larger: $7.6B against $7.5B for Kiniksa Pharmaceuticals International. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $677.6M for Kiniksa Pharmaceuticals International.

Which has the higher operating margin?

Alkermes: 17.2%, against 11.4% for Kiniksa Pharmaceuticals International. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Alkermes and Kiniksa Pharmaceuticals International?

In their latest 13F filings, Julian and Felix Baker holds both.

Cite this page

Funkfolio, “Alkermes vs Kiniksa Pharmaceuticals International”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-knsa

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.